Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of DKK 220.96 billion. The enterprise value is 242.86 billion.
Important Dates
The last earnings date was Thursday, November 5, 2026.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 63.30 million shares outstanding. The number of shares has decreased by -1.08% in one year.
| Current Share Class | 63.30M |
| Shares Outstanding | 63.30M |
| Shares Change (YoY) | -1.08% |
| Shares Change (QoQ) | +0.58% |
| Owned by Insiders (%) | 1.10% |
| Owned by Institutions (%) | 60.95% |
| Float | 58.96M |
Valuation Ratios
The trailing PE ratio is 45.37 and the forward PE ratio is 32.12. Genmab's PEG ratio is 1.50.
| PE Ratio | 45.37 |
| Forward PE | 32.12 |
| PS Ratio | 7.83 |
| PB Ratio | 5.31 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 39.52 |
| P/OCF Ratio | 38.44 |
| PEG Ratio | 1.50 |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 26.88, with an EV/FCF ratio of 43.43.
| EV / Earnings | 50.70 |
| EV / Sales | 8.60 |
| EV / EBITDA | 26.88 |
| EV / EBIT | 28.09 |
| EV / FCF | 43.43 |
Financial Position
The company has a current ratio of 2.45, with a Debt / Equity ratio of 0.82.
| Current Ratio | 2.45 |
| Quick Ratio | 2.43 |
| Debt / Equity | 0.82 |
| Debt / EBITDA | 3.78 |
| Debt / FCF | 6.11 |
| Interest Coverage | 3.49 |
Financial Efficiency
Return on equity (ROE) is 12.07% and return on invested capital (ROIC) is 12.73%.
| Return on Equity (ROE) | 12.07% |
| Return on Assets (ROA) | 8.24% |
| Return on Invested Capital (ROIC) | 12.73% |
| Return on Capital Employed (ROCE) | 11.31% |
| Weighted Average Cost of Capital (WACC) | 7.06% |
| Revenue Per Employee | 8.71M |
| Profits Per Employee | 1.48M |
| Employee Count | 3,244 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 14.32 |
Taxes
In the past 12 months, Genmab has paid 322.46 million in taxes.
| Income Tax | 322.46M |
| Effective Tax Rate | 6.30% |
Stock Price Statistics
The stock price has increased by +76.05% in the last 52 weeks. The beta is 0.52, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | +76.05% |
| 50-Day Moving Average | 2,850.84 |
| 200-Day Moving Average | 2,082.41 |
| Relative Strength Index (RSI) | 60.01 |
| Average Volume (20 Days) | 231,982 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genmab had revenue of DKK 28.27 billion and earned 4.80 billion in profits. Earnings per share was 76.95.
| Revenue | 28.27B |
| Gross Profit | 26.20B |
| Operating Income | 8.66B |
| Pretax Income | 5.12B |
| Net Income | 4.80B |
| EBITDA | 8.92B |
| EBIT | 8.66B |
| Earnings Per Share (EPS) | 76.95 |
Full Income Statement Balance Sheet
The company has 12.31 billion in cash and 34.21 billion in debt, with a net cash position of -21.89 billion or -345.91 per share.
| Cash & Cash Equivalents | 12.31B |
| Total Debt | 34.21B |
| Net Cash | -21.89B |
| Net Cash Per Share | -345.91 |
| Equity (Book Value) | 41.68B |
| Book Value Per Share | 658.45 |
| Working Capital | 12.43B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 5.76 billion and capital expenditures -157.94 million, giving a free cash flow of 5.60 billion.
| Operating Cash Flow | 5.76B |
| Capital Expenditures | -157.94M |
| Depreciation & Amortization | 272.59M |
| Net Borrowing | 35.44B |
| Free Cash Flow | 5.60B |
| FCF Per Share | 88.48 |
Full Cash Flow Statement Margins
Gross margin is 92.67%, with operating and profit margins of 30.63% and 16.97%.
| Gross Margin | 92.67% |
| Operating Margin | 30.63% |
| Pretax Margin | 18.11% |
| Profit Margin | 16.97% |
| EBITDA Margin | 31.56% |
| EBIT Margin | 30.63% |
| FCF Margin | 19.13% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.08% |
| Shareholder Yield | 1.08% |
| Earnings Yield | 2.20% |
| FCF Yield | 2.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside | |
Analyst Forecast
The average price target for Genmab is 4,195.23, which is 20.17% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 4,195.23 |
| Price Target Difference | 20.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | 26.11% |
| EPS Growth Forecast (3Y) | 22.60% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genmab has an Altman Z-Score of 3.02 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.02 |
| Piotroski F-Score | 4 |